SureTrader
Interactive Brokers Advertisement
Home > Boards > Free Zone > Penny Trading - Technical > MOMO'S BREAKOUT BOARD

ENUM .0068 MERCK: collaboration with a leading immuno-oncology

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Cheeky Member Profile
Member Level 
Followed By 856
Posts 113,243
Boards Moderated 6
Alias Born 08/25/10
160x600 placeholder
Cheeky Member Level  Friday, 10/06/17 12:33:11 PM
Re: None
Post # of 1818792 
ENUM .0068 MERCK: collaboration with a leading immuno-oncology pharmaceutical company
– Focused on using Enumeral's platform to interrogate the tumor microenvironment in colorectal cancer
tissues to identify functional cellular responses to therapies being developed by Merck
– R&D funding and undisclosed milestone payments
– Merck has exclusive rights to data related to its proprietary compounds
– ENUM has achieved first milestone in the collaboration
– Expanded scope of work to include non-small cell lung cancer
• NCI: awarded Phase 2 contract in September 2014 for ~$1 million over two years
– Automation of human tissue immuno-oncology profiling
– Opens door to broader pipeline and potentially accelerated development
– Collaboration with leading scientists:
– Jedd Wolchok’s group at MSKCC - genetic basis for response to checkpoint inhibitors and novel immunotherapeutics
– Doug Kwon’s group at MGH/Ragon Institute - pioneering techniques for single cell immune cell analysis in biopsy


Everything I say is in my opinion, do your own DD and make your decision wisely! Don't spend more then you can afford to lose!
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist